… lower––suggestive either of NMD degradation … exon 1 and upstream of exon 2. Both PRPH2
and NF1 have the start AUG encoded by exon 1; when transcription does not initiate at exon …

… the strongest relation to clinical outcome. Their assessment … affected exons 14, 15, 16 and
18 in SF3B1 and exon 34 in … not add significant prognostic value either in the 11q deleted …

… Last, 94% of patients (n = 47) had an EGFR exon 20 insertion mutation, and three patients
had either individual or compound point mutations in exon 20. A list of patients’ mutations is …

… patient to target the EGFRex20 + tumor effectively, and achieve clinical benefit. Osimertinib
cannot be routinely recommended at either 80 or 160 mg daily for patients with EGFRex20 + …

… This could either be a consequence of a … outcomes of PD-L1 blockade were worse in NSCLC
patients harboring mutations in exon 19 of EGFR, but not with the L858R variant in exon 21…

… have poor clinical outcomes, particularly those with non-BRCA gene alterations. HRD
score calculated from a targeted exome panel did not discern disparate clinical outcomes. …

… of exon 14 in MET can result from point mutations, insertions or deletions, or large-scale
whole-exon … splicing sites at the acceptor or donor site flanking MET exon 14. As a result of MET …

… 3 components of the primary outcome were combined using … on the multivariate outcome
being rejected for either large … years for DMD, 13 including exon skipping and read-through …

… Published dysregulated splicing events can be categorized as exon inclusion, exon exclusion,
splicing factor up-regulation, or splice site alterations. We observe these phenomena in …

… 327T>A allele with a pseudoexon of 28 bp spliced between exon 9 and exon 10 and
transcripts expressed by the c.810+1G>T allele lacking either exon 7 or both exon 6 and 7. In …